Evidence map›Paper›PMID 41694596›Full record

ReviewInternational journal of biological sciences2026

O-glycosylation in Cancer: Emerging Paradigms and Prospects for Precision Oncology.

Junhao Wei, Shengbao Hu, Wanfang Chen, Hye Song Paek, Guohong Liu, Yunbao Pan

Abstract readReview
In one paragraph

Review in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junhao WeiDepartment of Laboratory Medicine, Jiayu Hospital, Zhongnan Hospital of Wuhan University (People's Hospital of Jiayu County), Xianning 437200, Hubei, China.
Shengbao HuDepartment of Laboratory Medicine, Jiayu Hospital, Zhongnan Hospital of Wuhan University (People's Hospital of Jiayu County), Xianning 437200, Hubei, China.
Wanfang ChenDepartment of Laboratory Medicine, Huanggang Central Hospital, Huanggang 438000, China.
Hye Song PaekDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.
Guohong LiuDepartment of Radiology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Yunbao PanDepartment of Laboratory Medicine, Jiayu Hospital, Zhongnan Hospital of Wuhan University (People's Hospital of Jiayu County), Xianning 437200, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

O-glycosylation is a key post-translational modification that profoundly shapes tumor biology by regulating cell proliferation, metastasis, and immune evasion. Aberrant O-glycosylation features truncated glycans such as Tn and sialyl-Tn antigens together with dysregulated glycosyltransferases and promotes oncogenesis in diverse malignancies. This review summarizes recent progress in elucidating the role of O-glycosylation in cancer with emphasis on its effects on cell-surface glycoproteins, intracellular signaling pathways, and emerging RNA modifications. Integration of multi-omics data and machine learning has transformed tumor classification and prognosis prediction through distinct glycosylation signatures and now supports personalized treatment strategies. Newly discovered O-glycosylation of RNA reveals additional regulatory layers and broadens the field of glycosylation research. Targeted interventions including glycosyltransferase inhibitors, gene editing, and combination with immunotherapy demonstrate promising therapeutic potential. Advanced high-throughput tools especially mass spectrometry and enzymatic release methods accelerate biomarker discovery and target validation. Collectively, this review underscores the multifaceted impact of O-glycosylation on cancer progression and treatment response while highlighting the urgent need for continued interdisciplinary collaboration to translate these findings into precision oncology and better patient outcomes.

Indexed as

NeoplasmsPrecision MedicineAnimalsGlycosylationHumansProtein Processing, Post-Translationalbiomarkersgene modificationo-glycosylationprotein modificationtumor microenvironment

Identifiers

PMID41694596
PMCPMC12905637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.